Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.34 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.34 |
| ▸ | CDK2 | P24941 | 5/20 | 0.33 |
| ▸ | BCL6 | P41182 | 1/20 | 0.31 |
| ▸ | CDC7 | O00311 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | RAD52 | P43351 | 1/20 | 0.31 |
| ▸ | KAT7 | O95251 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4248122 | 0.80 | RPS6KA3 (0.36) | RPS6KA3KCNH2CDK2BCL6CDC7 | |
| SCHEMBL273281 | 0.77 | KCNH2 (0.54) | KCNH2CDK2 | |
| SCHEMBL1448068 | 0.73 | CYP11B2 (0.34) | RPS6KA3KCNH2CDK2CDC7KDM4E | |
| SCHEMBL4246503 | 0.72 | ALDH1A1 (0.38) | RPS6KA5KCNH2CDK2KDM4EADORA1 | |
| SCHEMBL6595714 | 0.72 | CDK2 (0.52) | CDK2CDC7KDM4E | |
| SCHEMBL4249428 | 0.70 | CDK2 (0.39) | CDK2CDC7 | |
| SCHEMBL633585 | 0.70 | PIK3CA (0.39) | KCNH2CDK2 | |
| SCHEMBL1155944 | 0.68 | KCNH2 (0.39) | KCNH2CDK2ADORA1 | |
| SCHEMBL4246511 | 0.68 | ADORA1 (0.32) | RPS6KA3BCL6CDC7KDM4EADORA1 | |
| SCHEMBL19497169 | 0.64 | CDK2 (0.40) | RPS6KA5CDK2KDM4EKAT7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099160-A1 | 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| EP-1828183-A1 | 4- (4- (IMIDAZOL-4-YL) PYRIMIDIN-2-YLAMINO) BENZAMIDES AS CDK INHIBITORS | AstraZeneca AB (SE) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006064251-A1 | 4- (4- (IMIDAZOL-4-YL) PYRIMIDIN-2-YLAMINO) BENZAMIDES AS CDK INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099160-A1 | 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors | CCNI, CDK4, CDK3 | RPS6KA3 612/4885RPS6KA5 536/4885KCNH2 3837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.